Macular edema is a pathological condition in which fluid and protein deposits accumulate within or beneath the macula — the central, cone-dense zone of the retina responsible for high-acuity central vision — causing it to thicken and swell. Unlike retinal detachment, which involves physical separation of retinal layers, macular edema is fundamentally a vascular permeability disorder in which breakdown of the blood–retinal barrier allows plasma constituents to leak into the macula’s extracellular and intracellular spaces. The underlying mechanism involves disruption of tight junctions between retinal vascular endothelial cells, often driven by pro-inflammatory cytokines (e.g., VEGF, IL-6) or elevated intravascular pressure, leading to fluid transudation into the outer plexiform and inner nuclear layers. Macular edema is always pathological — it has no physiological form — and its most common etiologies are diabetic retinopathy (diabetic macular edema, DME), retinal vein occlusion (RVO), cataract surgery complications (cystoid macular edema, CME), uveitis, and age-related macular degeneration (AMD). The clinically relevant subtypes most commonly encountered in coding include retinal edema (H35.81), diabetic macular edema (coded under the E08–E13 diabetes series with 5th/6th/7th character specificity), and cystoid macular edema following cataract surgery (H59.031, H59.032, H59.033). Macular edema is commonly confused with macular degeneration (AMD) — the key difference is that AMD involves degenerative structural changes to the macula (drusen, RPE atrophy, neovascularization), whereas macular edema is specifically fluid accumulation that may be transient and reversible with treatment.
The anatomical term macula entered English in the 1650s as a Latin borrowing meaning “spot” or “stain,” applied in ophthalmology specifically to the macula lutea (“yellow spot”) of the retina. The term edema entered English in the 1400s, from Greek oidēma (“a swelling”), derived from the verb oidein (“to swell”) — literally “a swelling of the macula.” The root macul- (“spot”) connects macular edema to the broader macul- root family: macula lutea (the yellow spot of the retina), maculopathy (macul- + -pathy → any disease of the macula), and macule (a flat, discolored skin lesion). The root edem- (“swelling”) is highly productive in medical terminology and appears in lymphedema, papilledema, angioedema, and cerebral edema.
🔀 ALIASES / ALTERNATE TERMS
Macular(adjective form — appears in “macular degeneration,” “macular hole,” “macular pucker/epiretinal membrane”)
Retinal Edema(clinical synonym; broader term encompassing fluid anywhere on the retina, not limited to the macular zone; coded as H35.81)
Cystoid Macular Edema (CME)(subtype characterized by cyst-like fluid pockets in the outer plexiform layer; most commonly post-cataract surgery; coded under H59.031, H59.032, H59.033)
Diabetic Macular Edema (DME)(etiologic subtype caused by diabetic retinopathy; requires coding under the diabetes E08–E13 series with full character specificity for type, severity, laterality, and macular edema status)
Uveitic Macular Edema (UME)(inflammation-driven subtype secondary to uveitis; coded under the underlying uveitis category — H20.xx — with additional code for retinal edema H35.81)
Clinically Significant Macular Edema (CSME)(clinical/historical term used pre-OCT to describe edema at or near the foveal center on fluorescein angiography; now largely replaced by OCT-defined center-involving vs. non-center-involving ME)
Center-Involving Macular Edema (CI-ME)(OCT-defined subtype where fluid extends into the foveal center; highest risk for vision loss; drives anti-VEGF treatment decisions)
Pseudophakic Cystoid Macular Edema (PCME) / Irvine-Gass Syndrome(CME occurring specifically after cataract surgery/IOL implantation; also called Irvine-Gass syndrome; coded H59.031–H59.033 by laterality)
🔗 RELATED TERMS
Macular Degeneration (AMD) — distinct from macular edema; AMD involves drusen deposition, RPE atrophy, and/or choroidal neovascularization causing permanent structural damage, whereas macular edema is reversible fluid accumulation; wet AMD can coexist with ME
Retinal Vein Occlusion (RVO) — common cause of macular edema; includes central retinal vein occlusion (H34.81x) and branch retinal vein occlusion (H34.83x); elevated venous pressure forces fluid into the macula
Diabetic Retinopathy — the most common systemic cause of macular edema; retinal microvascular damage from chronic hyperglycemia leads to VEGF overexpression and blood–retinal barrier breakdown
Uveitis — inflammatory cause of macular edema; cytokine-mediated vascular permeability increase drives fluid accumulation; requires treating the underlying inflammation to resolve ME
VEGF (Vascular Endothelial Growth Factor) — the primary molecular mediator of vascular permeability and angiogenesis in macular edema; the target of anti-VEGF intravitreal injection therapy (bevacizumab, ranibizumab, aflibercept, faricimab)
Epiretinal Membrane / Macular Pucker — fibrocellular membrane on the inner retinal surface that can cause traction-related macular thickening, mimicking or co-occurring with macular edema; differentiated by OCT
Macular Hole — full-thickness defect of the fovea; distinct from macular edema but shares OCT-based diagnosis; surgical repair via pars plana vitrectomy (67042)
Optical Coherence Tomography (OCT) — the gold-standard imaging modality for diagnosing, grading, and monitoring macular edema; cross-sectional retinal imaging quantifies central macular thickness (CMT)
Fluorescein Angiography (FA) — dye-based imaging used to evaluate vascular leakage patterns in macular edema; especially useful for identifying the source of leakage in DME and RVO-associated ME
Cataract Surgery — post-surgical cause of cystoid macular edema (Irvine-Gass syndrome); occurs in 1–3% of cataract extractions, typically within weeks postoperatively
Papilledema — fluid accumulation at the optic disc (not the macula); shares the edem- root but is a distinct entity caused by elevated intracranial pressure, not retinal vascular leakage
Intravitreal injection of pharmacologic agent (separate procedure) — primary treatment code for anti-VEGF injections (bevacizumab, ranibizumab, aflibercept, faricimab) and steroid implants for DME, RVO-ME, and uveitic ME
Destruction of localized lesion of retina (e.g., macular edema, tumors), 1 or more sessions; photocoagulation — focal laser photocoagulation; link to H35.81 per AAPC guidance
Treatment of extensive or progressive retinopathy (e.g., diabetic retinopathy), photocoagulation — panretinal photocoagulation (PRP); used for proliferative DR, not specifically for focal ME
Pars plana vitrectomy with removal of internal limiting membrane (ILM) (e.g., for repair of macular hole, diabetic macular edema), includes intraocular tamponade if performed — surgical option for refractory DME
67516
Suprachoroidal space injection of pharmacologic agent (separate procedure) — effective 1/1/2024; used for suprachoroidal triamcinolone acetonide (Xipere) for uveitic ME
Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina — OCT of the retina; primary imaging tool for diagnosing and monitoring macular edema thickness
Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral — used to evaluate vascular leakage patterns in ME workup
⚠️ Coding Note:macular edema coding is highly etiology-dependent — never default to H35.81 when a more specific cause is documented. When diabetic macular edema is documented, you must use the E08–E13 series with full 7-character specificity capturing diabetes type, retinopathy severity, macular edema status, and laterality (right = 1, left = 2, bilateral = 3, unspecified = 9); the diabetes code alone captures the ME — do not add H35.81 as an additional code. When the documentation states “cystoid macular edema following cataract surgery,” use H59.031–H59.033 rather than H35.81, as these are the more specific post-procedural codes. A common inpatient profee undercoding miss: when the physician documents “macular thickening,”“increased central macular thickness on OCT,” or “CMT elevated” — these are documentation triggers that should prompt a query to confirm macular edema and capture the specific etiology (diabetic? post-surgical? RVO-related?), which significantly impacts DRG weight and medical necessity for anti-VEGF authorization. For CPT 67028 (intravitreal injection), payers require the HCPCS drug code (e.g., J0178 for aflibercept, J2778 for ranibizumab, J9035 for bevacizumab) billed alongside the procedure code; the diagnosis code linked must match the FDA-approved indication for the specific drug to avoid medical necessity denials.
Crystal's Coder Hub